Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 2727.20, up by 51.05 points or 1.91% from its previous closing of Rs. 2676.15 on the BSE.

The scrip opened at Rs. 2685.00 and has touched a high and low of Rs. 2732.00 and Rs. 2685.00 respectively. So far 19011 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3689.00 on 20-Jul-2016 and a 52 week low of Rs. 2525.25 on 12-May-2017.

Last one week high and low of the scrip stood at Rs. 2,732.00 and Rs. 2,525.25 respectively. The current market cap of the company is Rs. 45182.02 crore.

The promoters holding in the company stood at 26.79%, while Institutions and Non-Institutions held 42.95% and 13.87% respectively.

Pharma major Dr Reddy’s Laboratories has unveiled the generic version of Sofosbuvir and Velpatasvir fixed-dose combination under the brandname Resof Total in India. The tablets are available in bottle count size of 28. It is used for the treatment of adult patients with chronic Hepatitis C Virus, Genotype 1,2,3,4,5 or 6 infection without cirrhosis or with compensated cirrhosis.

The Sofosbuvir 400mg and Velpatasvir 100 mg fixed-dose combination is a generic version of Gilead’s brand Epclusa. Treatment with this combination achieves a cure rate of more than 90 per cent in all genotypes of Hepatitis C virus.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.